The September 10, 2016 article by Gounder et al, entitled “Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma,” (Journal of Clinical Oncology 34:3166-3174) was published with an error of omission.
The list of funders under the Research Funding header for author Albiruni Ryan Abdul Razak should have included NIH grant P30 CA008748. The list of funders was given as: Merck, Karyopharm Therapeutics, Novartis, EntreMed, Pfizer, MedImmune, Bristol-Myers Squibb, Genentech, Boston Biomedical, Boehringer Ingelheim. Instead, it should have read as: Merck, Karyopharm Therapeutics, Novartis, EntreMed, Pfizer, MedImmune, Bristol-Myers Squibb, Genentech, Boston Biomedical, Boehringer Ingelheim, NIH Grant P30 CA008748.
The online version has been corrected in departure from the print. The authors regret the omission.